Technical Analysis for BCYC - Bicycle Therapeutics plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Inside Day | Range Contraction | -0.87% | |
| Oversold Stochastic | Weakness | -0.87% | |
| Stochastic Reached Oversold | Weakness | 1.44% | |
| Down 3 Days in a Row | Weakness | 1.44% | |
| Down 4 Days in a Row | Weakness | 1.44% | |
| Oversold Stochastic | Weakness | 1.44% | |
| 20 DMA Resistance | Bearish | -1.79% | |
| MACD Bearish Centerline Cross | Bearish | -1.79% | |
| MACD Bearish Signal Line Cross | Bearish | -1.79% | |
| Down 3 Days in a Row | Weakness | -1.79% |
| Alert | Time |
|---|---|
| Down 2 % | about 1 hour ago |
| 60 Minute Opening Range Breakdown | about 1 hour ago |
| Fell Below Previous Day's Low | about 2 hours ago |
| 60 Minute Opening Range Breakout | about 4 hours ago |
| Up 1% | about 4 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/02/2024
Bicycle Therapeutics plc Description
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Disease Immunology Oncology Tumor Ophthalmology Hematology Immune Checkpoint Cancer Research Search Technology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.9 |
| 52 Week Low | 12.54 |
| Average Volume | 361,722 |
| 200-Day Moving Average | 20.21 |
| 50-Day Moving Average | 23.64 |
| 20-Day Moving Average | 23.23 |
| 10-Day Moving Average | 23.25 |
| Average True Range | 1.28 |
| RSI (14) | 43.82 |
| ADX | 19.08 |
| +DI | 21.55 |
| -DI | 19.93 |
| Chandelier Exit (Long, 3 ATRs) | 22.93 |
| Chandelier Exit (Short, 3 ATRs) | 25.44 |
| Upper Bollinger Bands | 24.78 |
| Lower Bollinger Band | 21.69 |
| Percent B (%b) | 0.22 |
| BandWidth | 13.30 |
| MACD Line | -0.18 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.1431 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 24.00 | ||||
| Resistance 3 (R3) | 24.06 | 23.57 | 23.72 | ||
| Resistance 2 (R2) | 23.57 | 23.16 | 23.54 | 23.63 | |
| Resistance 1 (R1) | 22.97 | 22.90 | 23.27 | 22.91 | 23.54 |
| Pivot Point | 22.48 | 22.48 | 22.64 | 22.45 | 22.48 |
| Support 1 (S1) | 21.88 | 22.07 | 22.18 | 21.82 | 21.18 |
| Support 2 (S2) | 21.39 | 21.81 | 21.36 | 21.09 | |
| Support 3 (S3) | 20.79 | 21.39 | 21.00 | ||
| Support 4 (S4) | 20.73 |
